… The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) … for SARS-CoV-2 infection which can directly target SARS-CoV-2. …

… The various kinds of pharmaceutical prophylactic options that may be followed to prevent …
applicable to its mode of action against the SARS coronavirus family.[ 95 ] The second group of …

… and manage drug shortages and help in investigations of new drug applications and uses. …
working in the pharmaceutical supply chain should be prepared to manage any potential …

… (SARS), one in China during 2002–2003 (SARS-CoV) and the other one confined to regions
of the Middle East (MERS-CoV), … At the end of 2019, a new coronavirus causing a severe …

… The safest and easiest way to produce pharmaceutical products for treatment of SARS-CoV-2
is the first strategy, to find potential molecules from manufactured medicines. It may be …

… a significant acute syndrome of coronavirus 2 (SARSCoV-2), … SARS-CoV-2 is another
type of Beta coronavirus that involves severe acute coronavirus respiration syndrome (SARS-CoV…

… , resilient biomedical and expertise in pharmaceutical domain could not appropriate any …
SARS-CoV and MERS-CoV could prove effective against the recent outbreak of SAR-CoV-2…

… disease, with management protocols changing constantly, … affected areas of economic
management, magistral preparation, … Economic management Increase in pharmaceutical spending…

… -based assay, and the two major proteases of SARS-CoV-2, PL protease and 3CL main …
SARS-CoV replication (14). In our assay, nelfinavir mesylate (1) showed inhibition of SARS-CoV-…

… for SARS infection in 2003; hence, it was named SARS-CoV-2 [2]… physical manifestations
and their management. Nevertheless, … and psychiatric evidence on SARS-CoV-2 are limited. …